


Drug Delivery Firm Integral BioSystems LLC to Exhibit at 2017 ARVO Annual Meeting in Baltimore, Maryland May 7-11, 2017

Integral BioSystems will display in Booth 3308 at the ARVO Annual Meeting from May 7 - 11, 2017, at the Baltimore Convention Center in Baltimore, Maryland.



BEDFORD, MASSACHUSETTS, USA,
May 5, 2017 /EINPresswire.com/ --

Bedford, MA – May 5, 2017 – [Integral BioSystems LLC](#), Boston area CRO specializing in ophthalmological pharmaceutical formulation development, will be in the spotlight as a participating exhibitor (Booth 3308) during the ARVO 2017 Annual Meeting of the [Association for Research in Vision and Ophthalmology](#) from May 7-May 11, 2017, to be held at the Baltimore Convention Center in Baltimore, Maryland.



We want to improve peoples' lives through improved drug treatment regimens."

Dr. Shikha Barman

With almost 25 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development, the firm's CEO and President, Dr. Shikha P. Barman, will be on hand to discuss the specific requirements of interested attendees. In addition, Integral BioSystems scientists will be presenting two posters about its internal

R&D programs, based on the company's drug delivery platform technologies, NanoM™ and OcuSurf™.

Sunday, May 7, 2017: OcuSurf-Mediated Antimicrobial Therapies to Treat Multi-Drug Resistant Ocular Infections

Program Number: 1084; Poster Board Number: B0372; 3:15 PM–5:00 PM

Wednesday, May 10, 2017: Sustained Release of Peptides to the Ocular Surface via NanoM™ Wafer
Program Number: 4103; Poster Board Number: B0103; 8:30 AM–10:15 AM

About the Symposium

The ARVO 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover subjects like Medicine, Eyesight, Vision, Ophthalmology, and Eye Health. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that nearly 11,000 people will participate in this Meeting.

About Integral BioSystems

Integral BioSystems is a specialty drug delivery contract research organization that offers an

integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Dave Karasic
Integral BioSystems, LLC
781-275-8059
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.